S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
66,000% upside on tiny biotech? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
66,000% upside on tiny biotech? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
66,000% upside on tiny biotech? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
66,000% upside on tiny biotech? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
OTCMKTS:HKMPY

Hikma Pharmaceuticals (HKMPY) Stock Forecast, Price & News

$45.74
0.00 (0.00%)
(As of 05/26/2023 ET)
Compare
Today's Range
$45.74
▼
$45.74
50-Day Range
$41.20
▼
$47.25
52-Week Range
$25.12
▼
$47.25
Volume
214 shs
Average Volume
1,448 shs
Market Capitalization
N/A
P/E Ratio
14.78
Dividend Yield
0.70%
Price Target
N/A
ProfileChartCompetitorsDividendHeadlinesShort Interest

HKMPY stock logo

About Hikma Pharmaceuticals (OTCMKTS:HKMPY) Stock

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

Receive HKMPY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HKMPY Stock News Headlines

May 5, 2023 | marketwatch.com
Hikma Pharmaceuticals rises Friday, still underperforms market
May 3, 2023 | marketwatch.com
Hikma Pharmaceuticals rises Wednesday, outperforms market
May 28, 2023 | Legacy Research (Affiliate) (Ad)
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
March 19, 2023 | finance.yahoo.com
Hikma Pharmaceuticals Full Year 2022 Earnings: EPS Misses Expectations
February 7, 2023 | uk.investing.com
Hikma Pharmaceuticals PLC (HIK)
January 31, 2023 | marketwatch.com
Hikma Pharmaceuticals rises Tuesday, outperforms market
January 24, 2023 | marketwatch.com
Hikma Pharmaceuticals falls Tuesday, underperforms market
December 27, 2022 | msn.com
Junshi inks licensing deal with Hikma for toripalimab; FDA filing still under review
May 28, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
December 26, 2022 | financialpost.com
Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
December 15, 2022 | marketwatch.com
Hikma Pharmaceuticals rises Thursday, outperforms market
October 9, 2022 | finance.yahoo.com
Hikma Pharmaceuticals PLC (HKMPY)
September 28, 2022 | reuters.com
HKMPY.PK - | Stock Price & Latest News | Reuters
September 25, 2022 | uk.finance.yahoo.com
Hikma Pharmaceuticals PLC (H5P.F)
August 30, 2022 | finance.yahoo.com
Hikma launches RYALTRIS™ seasonal allergic rhinitis nasal spray in the US
July 17, 2022 | benzinga.com
Hikma Pharmaceuticals (OTC:HKMPY), Analyst Ratings, Price Targets, Predictions
May 24, 2022 | news.yahoo.com
Drugmaker Hikma's CEO Olafsson to step down
May 14, 2022 | finance.yahoo.com
Investors in Hikma Pharmaceuticals (LON:HIK) have unfortunately lost 26% over the last year
April 21, 2022 | finance.yahoo.com
Hikma completes acquisition of Custopharm
April 20, 2022 | seekingalpha.com
Hikma gets preliminary approval from FTC to acquire Custopharm
April 20, 2022 | finance.yahoo.com
Hikma confirms FTC preliminary approval for Custopharm
April 19, 2022 | finance.yahoo.com
U.S. FTC approves Hikma deal for Custopharm with conditions
February 27, 2022 | finance.yahoo.com
Analysts Have Made A Financial Statement On Hikma Pharmaceuticals PLC's (LON:HIK) Yearly Report
November 9, 2021 | finance.yahoo.com
Those who invested in Hikma Pharmaceuticals (LON:HIK) five years ago are up 62%
October 22, 2021 | finance.yahoo.com
Hikma donates 50,000 doses of injectable naloxone to help expand non-profit access to lifesaving treatment for reversing opioid overdoses
September 27, 2021 | finance.yahoo.com
Hikma Bolsters Injectable Portfolio With $375M Custopharm Acquisition
September 27, 2021 | finance.yahoo.com
Hikma strengthens US Injectables business through acquisition of Custopharm
See More Headlines
Receive HKMPY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HKMPY Company Calendar

Ex-Dividend for 5/15 Dividend
3/23/2023
Dividend Payable
5/15/2023
Today
5/28/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HKMPY
CUSIP
N/A
CIK
N/A
Web
www.hikma.com
Phone
442073992760
Fax
N/A
Employees
8,700
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
14.78
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Said Samih Taleb Darwazah
    Executive Chairman & Chief Executive Officer
  • Khalid Walid Hosni Nabilsi
    Chief Financial Officer
  • Mazen Samih Taleb Darwazah
    Executive Vice Chairman & President-MENA Region
  • Majda Labadi
    Executive VP-Organizational Development
  • Riad Mishlawi
    President-Injectables Division

Key Competitors

View All Competitors













HKMPY Stock - Frequently Asked Questions

How have HKMPY shares performed in 2023?

Hikma Pharmaceuticals' stock was trading at $36.95 at the beginning of the year. Since then, HKMPY stock has increased by 23.8% and is now trading at $45.74.
View the best growth stocks for 2023 here.

Are investors shorting Hikma Pharmaceuticals?

Hikma Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totaling 100 shares, a decrease of 98.0% from the April 30th total of 5,000 shares. Based on an average trading volume of 2,300 shares, the days-to-cover ratio is presently 0.0 days.
View Hikma Pharmaceuticals' Short Interest.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a dividend on Friday, March 17th. Investors of record on Friday, March 24th will be paid a dividend of $0.72 per share on Monday, May 15th. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, March 23rd. This is a positive change from the stock's previous dividend of $0.36.
Read our dividend analysis for HKMPY.

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals (OTCMKTS:HKMPY) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.65%. The dividend payout ratio is 10.34%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for HKMPY.

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPY."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPY stock can currently be purchased for approximately $45.74.

How many employees does Hikma Pharmaceuticals have?

The company employs 8,700 workers across the globe.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at 442073992760.

This page (OTCMKTS:HKMPY) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -